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Abstract: Several studies have suggested that the endocannabinoid system plays significant roles in the vulnerability  
to psychiatric disorders including drug abuse. To examine the possible association of the CNR1 and CNR2 genes, which 
encode cannabinoid receptors CB1 and CB2, with methamphetamine dependence, we investigated three single nucleotide 
polymorphisms (SNPs) (rs806379, rs1535255, rs2023239) in intron 2 of the CNR1 gene and a nonsynonymous SNP, 
Q63R, in the CNR2 gene. The study samples consisted of 223 patients with methamphetamine dependence and 292  
age- and sex- matched controls. There were no significant differences between the patients and controls in genotypic or  
allelic distribution of any SNP of the CNR1 and CNR2 genes. We also analyzed the clinical features of methamphetamine 
dependence. Rs806379 of the CNR1 gene showed a significant association with the phenotype of latency of psychosis  
after the first consumption of methamphetamine. Patients with the T allele or T-positive genotypes (T/T or A/T) may  
develop a rapid onset of psychosis after methamphetamine abuse. The present study suggests a possibility that genetic 
variants of the CNR1 gene may produce a liability to the complication of psychotic state after abuse of methamphetamine; 
however, our findings need to be confirmed by future replications. 
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INTRODUCTION 
  The endocannabinoid system is involved in vulnerability 
to psychiatric disorders including substance abuse [1]. There 
are two well-characterized cannabinoid receptors (CNRs), 
CNR1/CB1 and CNR2/CB2, that mediate endocannabinoid 
signaling [2]. CNR1 is distributed widely throughout the 
brain regions important for drug reward and drug memories, 
including the hippocampus, striatum, and cerebral cortex [3-
6]. In animal studies, it was suggested that modulation of 
endogenous central cannabinoid signaling in the mesolimbic 
pathways may be one component of the addiction process, 
particularly  via interaction with opioid and dopaminergic 
systems. CNR1 knock-out mice display alterations in reward 
and drug-seeking behaviors in response to several sub-
stances, including nicotine [7, 8], ethanol [9, 10], ampheta-
mine, cocaine, and other psychostimulants [11], and similar 
results were obtained after the blockade of CNR1 with   
the selective CNR1 antagonist, SR141716A [5, 12]. Some 
clinical studies have suggested that genetic variants of the  
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CNR1 gene might be associated with susceptibility to sub-
stance dependence [13-19]. The polymorphism of the CNR1 
genethat has been most widely studied is the (AAT)n 
trinucleotide short-tandem repeat. Comings et al. firstly re-
ported that long (AAT)n repeats were associated with intra-
venous administration of drugs of abuse [15], but the result 
has not been confirmed by other studies [20-23]. Recently, 
Zhang et al. reported that the ‘TAG’ haplotype consisting of 
rs806379, rs1535255, and rs2023239 in the 5’ region of the 
CNR1 gene was related to polysubstance abuse in both 
European-Americans and African-Americans and also to 
alcohol dependence in Japanese [24]. They also showed that 
individuals carrying one copy of the ‘TAG’ haplotype 
showed lower levels of mRNA expression in the brain than 
non-carriers. 
  On the other hand, CNR2 has been traditionally referred 
to as the peripheral cannabinoid receptor because CNR2 is 
expressed mainly in some peripheral and immune cells [25-
27]. However, recent studies demonstrated that CNR2 is also 
expressed in some regions of the brain and is supposed to be 
associated with addiction vulnerability as a modulator of the 
reward system [28-31]. A genetic variant of the CNR2 gene, 
Q63R, has been reported to be associated with autoimmune 
diseases [32] and osteoporosis [33]. Recently, Ishiguro et al. 
demonstrated that the variant is also associated with alcohol-184    Current Neuropharmacology, 2011, Vol. 9, No. 1  Okahisa et al. 
ism in Japanese [34] and depression [35]. These findings 
suggest that CNR1 and CNR2 may be involved in substance 
abuse and endogenous psychosis. Based on the above ration-
ale, we investigated the association between the CNR1 and 
CNR2 genes and methamphetamine dependence and psycho-
sis in a Japanese population. 
METHODS 
Subjects 
  The subjects comprised 224 unrelated patients with 
methamphetamine dependence (178 males and 46 females, 
average age 37.0 ± 11.9 years) who met the ICD-10-DCR 
criteria (F15.2). Two hundred and six of these patients have 
or had comorbid methamphetamine psychosis (F15.5). They 
were in- or outpatients of psychiatric hospitals of the Japa-
nese Genetics Initiative for Drug Abuse (JGIDA). The 
healthy controls were 292 normal, unrelated, age-, sex-, and 
geographical origin-matched individuals (228 males and 64 
females, average age 37.2 ± 13.1 years). Most were medical 
staff members who had no past history or family history of 
substance dependence or major psychotic disorder. All sub-
jects were Japanese, born and living in restricted areas of 
Japan, including northern Kyushu, Setouchi, Chukyo, Tokai, 
and Kanto, regions whose genetic background is considered 
to represent relative unity. This study was initiated after re-
ceiving the approval of the ethical committees of the partici-
pating institutions of the JGIDA. Written informed consent 
was obtained from all participants. 
Clinical Phenotypes 
  Clinical observation has revealed substantial inter-
individual differences in certain phenotypes of metham-
phetamine-taking behavior and psychosis that seem to be 
regulated, at least in part, genetically, and the rationale and 
methods of the subgrouping were previously described [36]. 
In brief, the patients with methamphetamine dependence and 
psychosis were divided into five subgroups according to the 
following clinical phenotypes: multisubstance-abuse status, 
age at first consumption of methamphetamine, latency to the 
onset of psychotic symptoms after the first consumption of 
methamphetamine, prognosis of psychosis after therapy, and 
the complication of spontaneous relapse to a psychotic state. 
Genotyping 
  Peripheral blood was obtained from the subjects, and the 
genomic DNA was extracted from peripheral leukocytes 
using a standard procedure. We selected four SNPs, 
rs806379, rs1535255 and rs2023239, of the CNR1 gene and 
a nonsynonymous polymorphism, Q63R, of the CNR2 gene, 
for genetic association analyses. The three SNPs of the 
CNR1 gene are located in the distal region of intron 2 and 
were reported to be associated with polysubstance abuse by 
Zhang  et al. [39]. Genotyping of the three SNPs of the 
CNR1 gene was performed using TaqMan technology on an 
ABI7500 Real Time PCR system (Applied Biosystems, 
U.S.A.). The genotypes of Q63R of the CNR2 gene were 
determined by the polymerase chain reaction (PCR)-
restriction fragment length polymorphism (RFLP) method as 
previously reported [34]. All genotyping was performed in a 
blinded fashion, with the control and case samples mixed 
randomly. 
Statistical Analysis 
  Statistical analysis of association was performed using 
SNPAlyze software (Dynacom Co., Japan). Deviation from 
Hardy-Weinberg equilibrium and the case-control study 
were tested using the 
2 test. Linkage disequilibrium (LD) 
was tested using the 
2 test, and D’ and r
2 values were made 
the index in the authorization of LD. Case-control haplotype 
analysis was performed by the permutation method, and 
permutation p values were calculated based on 100,000 rep-
lications. 
RESULTS 
  The genotype distribution and allele frequencies for each 
polymorphism of patients with methamphetamine depend-
ence and control subjects are shown in Table 1. The geno-
type distributions of patients with methamphetamine de-
pendence and control subjects did not deviate from Hardy-
Weinberg equilibrium at any of the four SNPs. We found no 
significant differences in genotypic or allelic distribution at 
any polymorphism of the CNR1 or CNR2 gene between the 
patients and controls. 
  We estimated the pairwise LD between the three SNPs of 
the CNR1 gene using the D’ and r
2 values as an index, and 
we found that rs806379, rs1535255, and rs2023239 showed 
a strong LD (D’ ranging from 0.90 to 0.99) with each other 
(Table 2). We then analyzed the 2- and 3-loci haplotype dis-
tribution, but no significant difference was found between 
patients of methamphetamine dependence and control sub-
jects (global permutation p value of 3-loci haplotype was 
0.34, Tables 3 and 4). 
  To investigate further the roles of CNR1 and CNR2 in 
the pathophysiology of psychosis and drug-taking behaviors, 
we examined the association of CNR1 and CNR2 genes with 
several clinical phenotypes of methamphetamine dependence 
and psychosis, such as the age at first consumption of meth-
amphetamine, latency to onset of psychosis after abuse, 
prognosis of psychosis after therapy, spontaneous relapse 
even without reconsumption of methamphetamine, and mul-
tiple substance abuse status, which show individual variation 
and may in part be regulated genetically. There was a sig-
nificant difference in the allelic distribution of rs806379 of 
the CNR1 gene between the two subgroups divided by la-
tency to onset of psychosis after methamphetamine abuse 
(Table 5). The T allele, a minor allele of rs806379, was more 
found frequently in the patients with a shorter latency to on-
set of psychosis than those with a longer latency (P=0.040). 
The patients with T-positive genotypes, A/T and T/T, also 
showed a shorter latency to onset of psychosis than those 
without (P=0.039). The other SNPs, rs1535255 and 
rs2023239 of the CNR1 and Q63R of the CNR2 gene, did 
not show an association with either phenotype (Table 5). 
DISCUSSION 
  The present study showed that the CNR1 and CNR2 
genes were not associated with methamphetamine depend-
ence/psychosis, but that the CNR1 gene was associated with 
one clinical phenotype: latency to the onset of psychotic 
symptoms after the first consumption of methamphetamine. 
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Table 1.  Genotype and Allele Frequencies of Three Single Nucleotide Polymorphisms of the CNR1 Gene and one SNP of the CNR2 
Gene in Patients with METH Dependence and/or Psychosis and Controls 
   Genotype(%)    P  Allele(%)   P 
CNR1 rs806379  N  A/A  A/T  T/T    A  T   
Controls 290  186(64.2)  92(31.7)  12(4.1)  0.49  464(80.0)  116(20.0)  0.23 
Patients 223  154(69.1)  62(27.8)  7(3.1)    370(83.0)  76(17.0)   
CNR1 rs1535255  N  T/T  T/G  G/G    T  G   
Controls 292  267(91.4)  25(85.6)  0(0)  0.87  559(95.7)  25(4.3)  0.87 
Patients 223  203(91.0)  20(9.0)  0(0)    426(95.5)  20(4.5)   
CNR1 rs2023239  N  T/T  T/C  C/C    T  C   
Controls 292  266(91.1)  26(8.9)  0(0)  0.97  558(95.5)  26(4.5)  0.97 
Patients 222  202(91.0)  20(9.0)  0(0)    424(95.5)  20(4.5)   
CNR2 Q63R  N  gg/gg(R/R)  gg/aa(R/Q)  aa/aa(Q/Q)    gg(Arg)  aa(Glu)   
Controls 281  93(33.1)  134(47.7)  54(19.2)  0.97  320(56.9)  242(43.1)  0.95 
Patients  223 72(32.3) 109(48.9) 42(18.8)   253(56.7)  193(43.3)   
 
Table 2.  Liskage Disequilibrium Analyses of three SNPs of the CNR1 Gene 
 rs806389  rs1535255  rs2023239 
rs806389   0.97  0.90 
rs1535255 0.19    0.98 
rs2023239 0.17  0.93   
Linkage disequilibrium (LD) was tested using 
2 test. 
Right upper and left lower diagonal showed D' and r-square values, respectively. 
 
Table 3.  Multi-Loci Association Analyses of the CNR1 Gene 
SNP  1 Locus  2 Loci  3 Loci 
rs806379 0.23     
   0.36   
rs1535255 0.87    0.34 
   0.56   
rs2023239 0.97     
 
Table 4.  Haplotype Frequencies of the CNR1 Gene 
rs806379/rs1535255/rs2023239 
Haplotype Control  Patient Permutation  p-value 
A-T-T 0.7944 0.8288  0.15 
T-T-T 0.159 0.1261  0.14   
T-G-C 0.0393 0.045  0.64 
Global permutation p-value = 0.34. 186    Current Neuropharmacology, 2011, Vol. 9, No. 1  Okahisa et al. 
Table 5.  Subgroups of METH Dependence and Psychosis by Clinical Characteristic 
Clinical Phenotype    Genotype(%)   P  Allele(%)   P 
CNR1 rs806379  N  A/A  A/T  T/T    A  T   
Multisubstance abuse 
Yes 157  109(69.4)  42(26.8)  6(3.8)  0.66  260(82.8)  54(17.2)  0.95 
No 59  40(67.8)  18(30.5)  1(1.7)    98(83.1)  20(16.9)   
Age at first consumption 
20 118  79(66.9)  37(31.4)  2(1.7)  0.21  195(82.6)  41(17.4)  0.84 
>20 102  73(71.6)  24(23.5)  5(4.9)    170(83.3)  34(16.7)   
Latency to onset of psychosis 
3 years  102  64(62.8)  34(33.3)  4(3.9)  0.12  162(79.4)  42(20.6)  0.04 
>3 years  93  71(76.3)  20(21.5)  2(2.2)    162(87.1)  24(12.9)   
Prognosis of psychosis 
Transient   113  76(67.3)  33(29.2)  4(3.5)  0.81  185(81.9)  41(18.1)  0.56 
Prolonged 91  65(71.4)  23(25.3)  3(3.3)    153(84.1)  29(15.9)   
Spontaneous relapse of psychosis 
Yes 93  69(74.2)  22(23.7)  2(2.1)  0.41  160(86.0)  26(14.0)  0.18 
No 119  79(66.4)  35(29.4)  5(4.2)    193(81.1)  45(18.9)   
CNR1 rs1535255  N  T/T  T/G  G/G    T  G   
Multisubstance abuse 
Yes 157  143(91.1)  14(8.9)  0(0.0)  0.78  300(95.5)  14(4.5)  0.78 
No 59  53(89.8)  6(10.2)  0(0.0)    112(94.9)  6(5.1)   
Age at first consumption 
20 118  108(91.5)  10(8.5)  0(0.0)  0.93  226(95.8)  10(4.2)  0.93 
>20 102  93(91.2)  9(8.8)  0(0.0)    195(95.6)  9(4.4)   
Latency to onset of psychosis 
3 years  102  91(89.2)  11(10.8)  0(0.0)  0.61  193(94.6)  11(5.4)  0.62 
>3 years  93  85(91.4)  8(8.6)  0(0.0)    178(95.7)  8(4.3)   
Prognosis of psychosis 
Transient   113  101(89.4)  12(10.6)  0(0.0)  0.47  214(94.7)  12(5.3)  0.49 
Prolonged 91  84(92.3)  7(7.7)  0(0.0)    175(96.2)  7(3.8)   
Spontaneous relapse of psychosis 
Yes 93  84(90.3)  9(9.7)  0(0.0)  0.58  177(95.2)  9(4.8)  0.59 
No 119  110(92.4)  9(7.6)  0(0.0)    229(96.2)  9(3.8)   
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Table 5. contd…. 
Clinical Phenotype    Genotype(%)   P  Allele(%)   P 
CNR1 rs2023239  N  T/T  T/C  C/C    T  C   
Multisubstance abuse 
Yes 156  142(91.0)  14(9.0)  0(0.0)  0.79  298(95.5)  14(4.5)  0.79 
No 59  53(89.8)  6(10.2)  0(0.0)    112(94.9)  6(5.1)   
Age at first consumption 
20 117  107(91.5)  10(8.5)  0(0.0)  0.94  224(95.7)  10(4.3)  0.94 
>20 102  93(91.2)  9(8.8)  0(0.0)    195(95.6)  9(4.4)   
Latency to onset of psychosis 
3 years  102  91(89.2)  11(10.8)  0(0.0)  0.61  193(94.6)  11(5.4)  0.62 
>3 years  93  85(91.4)  8(8.6)  0(0.0)    178(95.7)  8(4.3)   
Prognosis of psychosis 
Transient   113  101(89.4)  12(10.6)  0(0.0)  0.49  214(94.7)  12(5.3)  0.50 
Prolonged 90  83(92.2)  7(7.8)  0(0.0)    173(96.1)  7(3.9)   
Spontaneous relapse of psychosis 
Yes 92  83(90.2)  9(9.8)  0(0.0)  0.57  175(95.1)  9(4.9)  0.58 
No 119  110(92.4)  9(7.6)  0(0.0)    229(96.2)  9(3.8)   
CNR2 Q63R  N  gg/gg(R/R)  gg/aa(R/Q)  aa/aa(Q/Q)    gg(Arg)  aa(Glu)   
Multisubstance abuse 
Yes 157  53(33.8)  74(47.1)  30(19.1)  0.64  180(57.3)  134(42.7)  0.46 
No  59  16(27.1) 31(52.5) 12(20.4)    63(53.4) 55(46.6)   
Age at first consumption 
20 119  37(31.1)  58(48.7)  24(20.2)  0.81  132(55.5)  106(44.5)  0.52 
>20 100  34(34.0)  49(49.0)  17(17.0)    117(58.5)  83(41.5)   
Latency to onset of psychosis 
3 years  102  33(32.4)  55(53.9)  14(13.7)  0.08  121(59.3)  83(40.7)  0.19 
>3  years  92  29(31.5) 39(42.4) 24(26.1)    97(52.7) 87(47.3)   
Prognosis of psychosis 
Transient   112  40(35.7)  53(47.3)  19(17.0)  0.41  133(59.4)  91(40.6)  0.18 
Prolonged  92  26(28.3) 45(48.9) 21(22.8)    97(52.7) 87(47.3)   
Spontaneous relapse of psychosis 
Yes 93  30(32.3)  43(46.2)  20(21.5)  0.69  103(55.4)  83(44.6)  0.84 
No 118  36(30.5)  61(51.7)  21(17.8)    133(56.4)  103(43.6)   
 
rs806379 showed a rapid onset of psychosis after metham-
phetamine abuse. This finding suggests that the CNR1 gene 
may contribute to a liability for the complication of psy-
chotic symptoms after psychostimulant abuse. 
 Zhang  et al. [24]
 reported that the ‘TAG’ haplotype con-
sisting of rs806379, rs1535255, and rs2023239 of the CNR1 
gene, the three SNPs of the CNR1 gene that we genotyped in 
the present study, were strongly associated with polysub-188    Current Neuropharmacology, 2011, Vol. 9, No. 1  Okahisa et al. 
stance abuse both in European- and African-Americans. Ad-
ditionally, they identified the ‘TAG’ haplotype in Japanese 
and found a significant association with alcoholism in Japa-
nese. To identify the functional effects of the ‘TAG’ haplo-
type, they measured the expression levels of CNR1 mRNAs 
and found striking differences in the CNR1 mRNA levels in 
the brains of those with the ‘TAG’ haplotype and the other 
haplotypes. In recent years, several studies have examined 
the associations of the CNR1 gene with substance abuse and 
dependence, but the results were not always consistent [13, 
14, 16-23, 37-40]. Our data indicated that the polymorphisms 
of the CNR1 gene affected the clinical course of metham-
phetamine psychosis, but not dependence, at least in a Japa-
nese population. 
  With regard to the CNR2 gene, Ishiguro et al. reported 
that the nonsynonymous polymorphism, Q63R, of the CNR2 
gene was associated with alcoholism in a Japanese popula-
tion [34], and they showed an association between the poly-
morphism and Japanese patients of depression in another 
study [35]. They also revealed that mice expressing alcohol 
preference showed reduced Cb2 gene expression in the brain 
[34]. Furthermore, a significant decrease of the levels of the 
CB2 mRNA has been reported to accompany clinical remis-
sion of schizophrenia [41]. However, our data indicate that 
the polymorphism of the CNR2 gene did not affect the risk 
of methamphetamine dependence and psychosis or the clini-
cal phenotypes of methamphetamine psychosis in a Japanese 
population. 
  Several concerns about the present study should be 
raised. We found a statistically significant association of the 
rs806379 of the CNR1 gene with one of the clinical pheno-
types, latency to the onset of psychotic symptoms after the 
first consumption of methamphetamine, but the p value was 
marginal. The possibility of type I errors should be consid-
ered. Further, we examined these three SNPs of the CNR1 
gene and one SNP of the CNR2 gene because they may have 
physiological effects, but there are many other SNPs in the 
CNR1 and CNR2 genes. Therefore, our findings must be 
confirmed in larger samples by examining additional SNPs 
to cover the entire CNR1 and CNR2 genes. Finally, the mi-
nor allele frequencies of the three SNPs of the CNR1 gene 
shown in Table 1 are markedly different from those reported 
by Zhang et al. [24]. The differences may be due to popula-
tion differences or a sample size not large enough for com-
parison. We reported the SNPs based on the NCBI refSNP 
marker database, which corresponds to the chromosome 6-
plus strand in each case. Zhang et al. have may used the base 
designation for the chromosome 6-minus strand for these 
markers. Accordingly, the ‘TAG’ haplotype reported by 
Zhang  et al. corresponded to the ‘ATC’ haplotype of our 
study. However, the ‘ATC’ haplotype was completely absent 
in our population. 
  In conclusion, this study showed that CNR1 variation 
may contribute to liability for complications of psychotic 
symptoms of methamphetamine abusers. Further research is 
needed to determine the possible association between endo-
cannabinoid system and substance dependence. 
ACKNOWLEDGEMENTS 
  We thank the Zikei Institute of Psychiatry (Okayama, 
Japan), the Ministry of Health, Labor, and Welfare and the 
Ministry of Education, Culture, Sports, Science and Tech-
nology of Japan. 
REFERENCES 
[1]  van der Stelt, M.; Di Marzo, V. The endocannabinoid system in the 
basal ganglia and in the mesolimbic reward system: implications 
for neurological and psychiatric disorders. Eur. J. Pharmacol., 
2003, 480, 133-150. 
[2]  Matsuda, L.A.; Lolait, S.J.; Brownstein, M.J.; Young, A.C.; Bon-
ner, T.I. Structure of a cannabinoid receptor and functional expres-
sion of the cloned cDNA. Nature, 1990, 346, 561-564. 
[3]  Herkenham, M.; Lynn, A.B.; Johnson, M.R.; Melvin, L.S.; de 
Costa, B.R.; Rice, K.C. Characterization and localization of can-
nabinoid receptors in rat brain: a quantitative in vitro autoradio-
graphic study. J. Neurosci., 1991, 11, 563-583. 
[4]  Herkenham, M.; Lynn, A.B.; Little, M.D.; Johnson, M.R.;   
Melvin, L.S.; de Costa, B.R.; Rice, K.C. Cannabinoid receptor   
localization in brain. Proc. Natl. Acad. Sci. USA, 1990, 87, 1932-
1936. 
[5]  Matsuda, L.A.; Bonner, T.I.; Lolait, S.J. Localization of cannabi-
noid receptor mRNA in rat brain. J. Comp. Neurol.,  1993,  327, 
535-550. 
[6]  Tsou, K.; Brown, S.; Sanudo-Pena, M.C.; Mackie, K.; Walker, J.M. 
Immunohistochemical distribution of cannabinoid CB1 receptors in 
the rat central nervous system. Neuroscience, 1998, 83, 393-411. 
[7]  De Vries, T.J.; Schoffelmeer, A.N. Cannabinoid CB1 receptors 
control conditioned drug seeking. Trends Pharmacol. Sci.,  2005, 
26, 420-426. 
[8]  Forget, B.; Hamon, M.; Thiebot, M.H. Cannabinoid CB1 receptors 
are involved in motivational effects of nicotine in rats. Psycho-
pharmacology (Berl), 2005, 181, 722-734. 
[9]  Colombo, G.; Serra, S.; Vacca, G.; Carai, M.A.; Gessa, G.L. Endo-
cannabinoid system and alcohol addiction: pharmacological stud-
ies. Pharmacol. Biochem. Behav., 2005, 81, 369-380. 
[10]  Racz, I.; Bilkei-Gorzo, A.; Toth, Z.E.; Michel, K.; Palkovits, M.; 
Zimmer, A. A critical role for the cannabinoid CB1 receptors in al-
cohol dependence and stress-stimulated ethanol drinking. J. Neuro-
sci., 2003, 23, 2453-2458. 
[11]  Maldonado, R.; Valverde, O.; Berrendero, F. Involvement of the 
endocannabinoid system in drug addiction. Trends Neurosci., 2006, 
29, 225-232. 
[12]  Yamamoto, T.; Takada, K. Role of cannabinoid receptor in the 
brain as it relates to drug reward. Jpn. J. Pharmacol., 2000, 84, 
229-236. 
[13]  Agrawal, A.; Wetherill, L.; Dick, D.M.; Xuei, X.; Hinrichs, A.; 
Hesselbrock, V.; Kramer, J.; Nurnberger, J.I., Jr.; Schuckit, M.; 
Bierut, L.J.; Edenberg, H.J.; Foroud, T. Evidence for association 
between polymorphisms in the cannabinoid receptor 1 (CNR1) 
gene and cannabis dependence. Am. J. Med. Genet. B Neuropsy-
chiatr. Genet., 2008, 150, 736-40. 
[14]  Chen, X.; Williamson, V.S.; An, S.S.; Hettema, J.M.; Aggen, S.H.; 
Neale, M.C.; Kendler, K.S. Cannabinoid receptor 1 gene associa-
tion with nicotine dependence. Arch. Gen. Psychiatry, 2008, 65, 
816-824. 
[15]  Comings, D.E.; Muhleman, D.; Gade, R.; Johnson, P.; Verde,   
R.; Saucier, G.; MacMurray, J. Cannabinoid receptor gene (CNR1): 
association with i.v. drug use. Mol. Psychiatry, 1997, 2, 161-168. 
[16]  Herman, A.I.; Kranzler, H.R.; Cubells, J.F.; Gelernter, J.; Covault, 
J. Association study of the CNR1 gene exon 3 alternative promoter 
region polymorphisms and substance dependence. Am. J. Med. 
Genet. B Neuropsychiatr. Genet., 2006, 141, 499-503. 
[17]  Hopfer, C.J.; Young, S.E.; Purcell, S.; Crowley, T.J.; Stallings, 
M.C.; Corley, R.P.; Rhee, S.H.; Smolen, A.; Krauter, K.; Hewitt, 
J.K.; Ehringer, M.A. Cannabis receptor haplotype associated with 
fewer cannabis dependence symptoms in adolescents. Am. J. Med. 
Genet. B Neuropsychiatr. Genet., 2006, 141, 895-901. 
[18]  Schmidt, L.G.; Samochowiec, J.; Finckh, U.; Fiszer-Piosik, E.; 
Horodnicki, J.; Wendel, B.; Rommelspacher, H.; Hoehe, M.R. As-
sociation of a CB1 cannabinoid receptor gene (CNR1) polymor-Association Study of Two Cannabinoid Receptor Genes  Current Neuropharmacology, 2011, Vol. 9, No. 1    189 
phism with severe alcohol dependence. Drug Alcohol Depend., 
2002, 65, 221-224. 
[19]  Zuo, L.; Kranzler, H.R.; Luo, X.; Covault, J.; Gelernter, J. CNR1 
variation modulates risk for drug and alcohol dependence. Biol. 
Psychiatry, 2007, 62, 616-626. 
[20]  Ballon, N.; Leroy, S.; Roy, C.; Bourdel, M.C.; Charles-Nicolas, A.; 
Krebs, M.O.; Poirier, M.F. (AAT)n repeat in the cannabinoid   
receptor gene (CNR1): association with cocaine addiction in   
an African-Caribbean population. Pharmacogenomics J., 2006, 6, 
126-130. 
[21]  Covault, J.; Gelernter, J.; Kranzler, H. Association study of   
cannabinoid receptor gene (CNR1) alleles and drug dependence. 
Mol. Psychiatry, 2001, 6, 501-502. 
[22]  Li, T.; Liu, X.; Zhu, Z.H.; Zhao, J.; Hu, X.; Ball, D.M.; Sham, P.C.; 
Collier, D.A. No association between (AAT)n repeats in the can-
nabinoid receptor gene (CNR1) and heroin abuse in a Chinese 
population. Mol. Psychiatry, 2000, 5, 128-130. 
[23]  Ponce, G.; Hoenicka, J.; Rubio, G.; Ampuero, I.; Jimenez-Arriero, 
M.A.; Rodriguez-Jimenez, R.; Palomo, T.; Ramos, J.A. Association 
between cannabinoid receptor gene (CNR1) and childhood atten-
tion deficit/hyperactivity disorder in Spanish male alcoholic pa-
tients. Mol. Psychiatry, 2003, 8, 466-467. 
[24]  Zhang, P.W.; Ishiguro, H.; Ohtsuki, T.; Hess, J.; Carillo, F.;   
Walther, D.; Onaivi, E.S.; Arinami, T.; Uhl, G.R. Human   
cannabinoid receptor 1: 5' exons, candidate regulatory regions,   
polymorphisms, haplotypes and association with polysubstance 
abuse. Mol. Psychiatry, 2004, 9, 916-931. 
[25]  Berdyshev, E.V. Cannabinoid receptors and the regulation of   
immune response. Chem. Phys. Lipids, 2000, 108, 169-190. 
[26]  Munro, S.; Thomas, K.L.; Abu-Shaar, M. Molecular characteriza-
tion of a peripheral receptor for cannabinoids. Nature, 1993, 365, 
61-65. 
[27]  Sugiura, T.; Waku, K. 2-Arachidonoylglycerol and the cannabinoid 
receptors. Chem. Phys. Lipids, 2002, 108, 89-106. 
[28]  Onaivi, E.S.; Carpio, O.; Ishiguro, H.; Schanz, N.; Uhl, G.R.; 
Benno, R. Behavioral effects of CB2 cannabinoid receptor activa-
tion and its influence on food and alcohol consumption. Ann. N. Y. 
Acad. Sci., 2008, 1139, 426-433. 
[29]  Onaivi, E.S.; Ishiguro, H.; Gong, J.P.; Patel, S.; Meozzi, P.A.; 
Myers, L.; Perchuk, A.; Mora, Z.; Tagliaferro, P.A.; Gardner, E.; 
Brusco, A.; Akinshola, B.E.; Hope, B.; Lujilde, J.; Inada, T.; Iwasaki, 
S.; Macharia, D.; Teasenfitz, L.; Arinami, T.; Uhl, G.R. Brain neu-
ronal CB2 cannabinoid receptors in drug abuse and depression: 
from mice to human subjects. PLoS ONE, 2008, 3, e1640. 
[30]  Onaivi, E.S.; Ishiguro, H.; Gong, J.P.; Patel, S.; Perchuk, A.; 
Meozzi, P.A.; Myers, L.; Mora, Z.; Tagliaferro, P.; Gardner, E.; 
Brusco, A.; Akinshola, B.E.; Liu, Q.R.; Hope, B.; Iwasaki, S.; Ari-
nami, T.; Teasenfitz, L.; Uhl, G.R. Discovery of the presence and 
functional expression of cannabinoid CB2 receptors in brain. Ann. 
N. Y. Acad. Sci., 2006, 1074, 514-536. 
[31]  Van Sickle, M.D.; Duncan, M.; Kingsley, P.J.; Mouihate, A.;   
Urbani, P.; Mackie, K.; Stella, N.; Makriyannis, A.; Piomelli, D.; 
Davison, J.S.; Marnett, L.J.; Di Marzo, V.; Pittman, Q.J.; Patel, 
K.D.; Sharkey, K.A. Identification and functional characterization 
of brainstem cannabinoid CB2 receptors. Science, 2005, 310, 329-
332. 
[32]  Sipe, J.C.; Arbour, N.; Gerber, A.; Beutler, E. Reduced endocan-
nabinoid immune modulation by a common cannabinoid 2 (CB2) 
receptor gene polymorphism: possible risk for autoimmune disor-
ders. J. Leukoc. Biol., 2005, 78, 231-238. 
[33]  Karsak, M.; Cohen-Solal, M.; Freudenberg, J.; Ostertag, A.; 
Morieux, C.; Kornak, U.; Essig, J.; Erxlebe, E.; Bab, I.; Kubisch, 
C.; de Vernejoul, M.C.; Zimmer, A. Cannabinoid receptor type 2 
gene is associated with human osteoporosis. Hum. Mol. Genet., 
2005, 14, 3389-3396. 
[34]  Ishiguro, H.; Iwasaki, S.; Teasenfitz, L.; Higuchi, S.; Horiuchi, Y.; 
Saito, T.; Arinami, T.; Onaivi, E.S. Involvement of cannabinoid 
CB2 receptor in alcohol preference in mice and alcoholism in   
humans. Pharmacogenomics J., 2007, 7, 380-385. 
[35]  Onaivi, E.S.; Ishiguro, H.; Gong, J.P.; Patel, S.; Meozzi, P.A.; 
Myers, L.; Perchuk, A.; Mora, Z.; Tagliaferro, P.A.; Gardner, E.; 
Brusco, A.; Akinshola, B.E.; Liu, Q.R.; Chirwa, S.S.; Hope, B.; 
Lujilde, J.; Inada, T.; Iwasaki, S.; Macharia, D.; Teasenfitz, L.; 
Arinami, T.; Uhl, G.R. Functional expression of brain neuronal 
CB2 cannabinoid receptors are involved in the effects of drugs of 
abuse and in depression. Ann. N. Y. Acad. Sci., 2008, 1139, 434-
449. 
[36]  Ujike, H.; Sato, M. Clinical features of sensitization to metham-
phetamine observed in patients with methamphetamine dependence 
and psychosis. Ann. N. Y. Acad. Sci., 2004, 1025, 279-287. 
[37]  Hartman, C.A.; Hopfer, C.J.; Haberstick, B.; Rhee, S.H.; Crowley, 
T.J.; Corley, R.P.; Hewitt, J.K.; Ehringer, M.A. The association be-
tween cannabinoid receptor 1 gene (CNR1) and cannabis depend-
ence symptoms in adolescents and young adults. Drug Alcohol De-
pend., 2009, 104, 11-16. 
[38]  Hoenicka, J.; Ponce, G.; Jimenez-Arriero, M.A.; Ampuero, I.; 
Rodriguez-Jimenez, R.; Rubio, G.; Aragues, M.; Ramos, J.A.; 
Palomo, T. Association in alcoholic patients between psychopathic 
traits and the additive effect of allelic forms of the CNR1 and 
FAAH endocannabinoid genes, and the 3' region of the DRD2 
gene. Neurotox. Res., 2007, 11, 51-60. 
[39]  Preuss, U.W.; Koller, G.; Zill, P.; Bondy, B.; Soyka, M. Alcohol-
ism-related phenotypes and genetic variants of the CB1 receptor. 
Eur. Arch. Psychiatry Clin. Neurosci., 2003, 253, 275-280. 
[40]  Zuo, L.; Kranzler, H.R.; Luo, X.; Yang, B.Z.; Weiss, R.; Brady, K.; 
Poling, J.; Farrer, L.; Gelernter, J. Interaction between two inde-
pendent CNR1 variants increases risk for cocaine dependence in 
European Americans: a replication study in family-based sample 
and population-based sample. Neuropsychopharmacology,  2009, 
34, 1504-1513. 
[41]  De Marchi, N.; De Petrocellis, L.; Orlando, P.; Daniele, F.; Fezza, 
F.; Di Marzo, V. Endocannabinoid signalling in the blood of   
patients with schizophrenia. Lipids Health Dis., 2003, 2, 5. 
 
 
Received: October 01, 2009  Revised: April 17, 2010  Accepted: May 26, 2010 
 
 